Acute and post-acute behavioral and psychological effects of salvinorin A in humans Peter H. Addy Psychopharmacology, 2012, 220, 195–204 DOI 10.1007/s00213-011-2470-6 Abstract Rationale : Salvia divinorum has been used for centuries, and nontraditional use in modern societies is increasing. Inebriation and aftereffects of use are poorly documented in the scientific literature. Objectives : This double-blind, placebo-controlled, randomized study analyzed subjective experiences of salvinorin A (SA) inebriation and consequences of use after 8 weeks. Methods : Thirty middle-aged, well-educated, hallucinogenexperienced participants smoked either 1,017 or 100μg SA 2 weeks apart in counterbalanced order. Vital signs were recorded before and after inhalation. A researcher rated participants' behavior during sessions. [...]
Lire la suiteLong-term follow-up of psilocybin-facilitated smoking cessation Johnson M.W., Garcia-Romeu A., Griffiths R.R. The American Journal of Drug and Alcohol Abuse, 2017, 43, (1), 55–60 http://dx.doi.org/10.3109/00952990.2016.1170135 Abstract Background : A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. Objectives : To assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration. Methods : The present [...]
Lire la suitePredicting Responses to Psychedelics : A Prospective Study Eline C. H. M. Haijen, Mendel Kaelen, Leor Roseman, Christopher Timmermann, Hannes Kettner, Suzanne Russ, David Nutt, Richard E. Daws, Adam D. G. Hampshire, Romy Lorenz and Robin L. Carhart-Harris Frontiers in Pharmacology, 2018 doi: 10.3389/fphar.2018.00897 Abstract Responses to psychedelics are notoriously difficult to predict, yet significant work is currently underway to assess their therapeutic potential and the level of interest in psychedelics among the general public appears to be increasing. We aimed to collect prospective data in order to improve our ability to predict acute- and longer-term responses to psychedelics. Individuals who planned to take a [...]
Lire la suiteQualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions Frederick S. Barrett, Hollis Robbins, David Smooke, Jenine L. Brown and Roland R. Griffiths Frontiers in Psychology, 2017 ORIGINAL RESEARCH published: 25 July 2017 doi: 10.3389/fpsyg.2017.01238 Abstract Psilocybin is a classic (serotonergic) hallucinogen (“psychedelic” drug) that may occasion mystical experiences (characterized by a profound feeling of oneness or unity) during acute effects. Such experiences may have therapeutic value. Research and clinical applications of psychedelics usually include music listening during acute drug effects, based on the expectation that music will provide psychological support during the acute effects of psychedelic drugs, and [...]
Lire la suiteEmotional breakthrough and psychedelics : Validation of the Emotional Breakthrough Inventory Leor Roseman, Eline Haijen, Kelvin Idialu-Ikato, Mendel Kaelen, Rosalind Watts and Robin Carhart-Harris Journal of Psychopharmacology, 2019, 1–12 DOI: 10.1177/0269881119855974 Abstract Background : Psychedelic therapy is gaining recognition and the nature of the psychedelic experience itself has been found to mediate subsequent long-term psychological changes. Much emphasis has been placed on the occurrence of mystical-type experiences in determining long-term responses to psychedelics yet here we demonstrate the importance of another component, namely: emotional breakthrough. Methods : Three hundred and seventy-nine participants completed online surveys before and after a planned psychedelic experience. Items pertaining to emotional [...]
Lire la suiteThe Meaning-Enhancing Properties of Psychedelics and Their Mediator Role in Psychedelic Therapy, Spirituality, and Creativity Ido Hartogsohn Frontiers in Neurosciences, 06 March 2018 | https://doi.org/10.3389/fnins.2018.00129 Past research has demonstrated to the ability of psychedelics to enhance suggestibility, and pointed to their ability to amplify perception of meaning. This paper examines the existing evidence for the meaning-enhancing properties of psychedelics, and argues that the tendency of these agents to enhance the perception of significance offers valuable clues to explaining their reported ability to stimulate a variety of therapeutic processes, enhance creativity, and instigate mystical-type experiences. Building upon previous research, which suggested the potential role of [...]
Lire la suiteDream over life : Psychedelic terphenyl derivative induce hallucination via cannabinoid receptor 1 F.A. Fauzi, M.S. Goh, S.A.T.T. Johari, F. Hashim, M.F.N. Hassim The International Fundamentum Sciences Symposium 2018 IOP Publishing IOP Conf. Series: Materials Science and Engineering 440 (2018) 012045 doi:10.1088/1757-899X/440/1/012045 Abstract. For ages, natural psychedelic resources have been used by ancient tribes for religious inspiration. In modern medicine, these compounds were prescribed to relieve severe distress and depression on cancer patients. Despite medical benefit, abuse of these compounds have become prevalent in our modern society. These compounds usually interacted withcannabinoid receptor 1 (CNR1) on neuron cell causing hallucination, and on other cell-types. In this [...]
Lire la suitePilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction Matthew W Johnson, Albert Garcia-Romeu, Mary P Cosimano and Roland R Griffiths Journal of Psychopharmacology, 2014, Vol. 28(11) 983–992 © The Author(s) 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav DOI: 10.1177/0269881114548296 Abstract Despite suggestive early findings on the therapeutic use of hallucinogens in the treatment of substance use disorders, rigorous follow-up has not been conducted. To determine the safety and feasibility of psilocybin as an adjunct to tobacco smoking cessation treatment we conducted an openlabel pilot study administering moderate (20 mg/70 kg) and high (30 mg/70 kg) doses of psilocybin within a structured 15-week smoking cessation treatment [...]
Lire la suiteThe World Ayahuasca Diaspora. Reinventions and controversies Forword. Ayahuasca in the twenty-first century : having it both ways Glenn H. Shepard Jr. Museu Paraense Emílio Goeldi Edited by Beatriz Caiuby Labate, Clancy Cavnar, and Alex K. Gearin janvier 2017 The genie is out of the bottle, tweeting about the next shamanic bodywork leadership seminar, and the bottle; well, check and see if it isn’t in the back of your fridge by the vegan TV dinner. Who would have ever imagined that ayahuasca, the enigmatic jungle potion William S. Burroughs once referred to as “the secret” (Burroughs & Ginsberg, 2006 [1963]) and whose very botanical identity was a matter [...]
Lire la suiteDark Classics in chemical Neuroscience : Lysergic Acid Diethylamide (LSD), David E. Nichols, ACS Chemical Neuroscience, 2018, 9, 10, 2331-2334. doi: 10.1021/acschemneuro.8b00043. Abstract : LSD is one of the most potent psychoactive agents known, producing dramatic alterations of consciousness after submilligram (≥20 g) oral doses. Following the accidental discovery of its potent psychoactive effects in 1943, it was supplied by Sandoz Laboratories as an experimental drug that might be useful as an adjunct for psychotherapy, or to give psychiatrists insight into the mental processes in their patients. The finding of serotonin in the mammalian brain in 1953, and its structural resemblance to LSD, quickly led [...]
Lire la suite